Maryland 2025 Regular Session

Maryland House Bill HB1310

Introduced
2/7/25  
Refer
2/7/25  
Report Pass
3/15/25  
Engrossed
3/17/25  
Refer
3/17/25  
Report Pass
4/4/25  

Caption

Prescription Drug Repository Program - Revisions

Impact

This legislation is expected to significantly impact state public health laws by creating a more inclusive framework for the donation and distribution of prescription and over-the-counter medications. Eligible recipients include individuals who are uninsured, underinsured, or enrolled in public health benefit programs, thereby expanding access to necessary medical treatments within the community. The bill also outlines procedures for ensuring compliance with state and federal laws regarding drug storage, distribution, and dispensing, alongside reinforcing the standards for donated medications.

Summary

House Bill 1310, titled 'Prescription Drug Repository Program - Revisions', seeks to enhance the existing Prescription Drug Repository Program in the state of Maryland. The bill allows pharmacy entities licensed in other states to be designated as repositories within the program. It expands the types of medications eligible for donation, specifically including over-the-counter drugs, and facilitates the procedural requirements for accepting these medications, aiming to increase the availability of medical supplies for needy individuals.

Sentiment

The sentiment surrounding HB 1310 appears to be positive with a focus on facilitating healthcare access and improving the current repository program. Supporters argue that the bill will address important public health needs by ensuring that more medications are available to those who need them, potentially reducing healthcare costs for individuals. However, the inclusion of out-of-state pharmacies raises some concerns regarding the regulation and safety of medications dispensed by these external entities, which could be a point of contention among medical professionals and consumer advocacy groups.

Contention

Notable points of contention arise from the bill's provision that allows out-of-state pharmacies to participate in the program as repositories. Critics may challenge the adequacy of oversight for these pharmacies and whether they will meet the same safety and quality standards that in-state pharmacies are required to uphold. Additionally, the bill's provisions for liability immunity for those involved in the donation and dispensing process may lead to ongoing debates about accountability, especially in cases where patients may suffer adverse effects from donated medications.

Companion Bills

No companion bills found.

Similar Bills

PA HB69

Further providing for title and short title of act, for definitions, for establishment, for restocking and dispensing of cancer drugs, for storage, distribution and fees and for immunity; providing for annual report and for list of approved participating pharmacies; further providing for regulations; and imposing duties on the State Board of Pharmacy.

MN SF1785

Medication repository program procedures modifications provision and appropriation

MN HF1103

Medication repository program procedures modified, and money appropriated.

MA H1374

Establishing a state-wide drug repository program

WI AB62

Health care costs omnibus, granting rule-making authority, making an appropriation, and providing a penalty. (FE)

WI SB50

Health care costs omnibus, granting rule-making authority, making an appropriation, and providing a penalty. (FE)

TX HB2271

Relating to a pilot program for donation and redistribution of certain unused prescription medications; authorizing a fee.

TX SB1243

Relating to a pilot program for donation and redistribution of certain unused prescription medications; authorizing a fee.